Surgical Therapy and Survival in HCC/ C.F. Zhang et al.

Hepatocellular Carcinoma Clinical Trial

Official title:

Surgical Therapy and Survival in Young Patients With Stage I-II Hepatocellular Carcinoma: A Retrospective Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04820712
• Other study ID #: FirstAHGTCMU
• Status: Completed
• Start date: September 1, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: March 2021
• Source: The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.

Description:

The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 664
• Est. completion date: January 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Patients were diagnosed with colorectal cancer only;

2. Patients with simultaneous metastasis of liver and lung cancer cells;

3. Patients without metastasis resection;

4. whether they underwent palliative primary tumor resection was known;

5. Their cause of death was known;

6. Their survival time were known and greater than 0 month;

7. Patients were diagnosed with microscopic confirmation.

Exclusion Criteria:

• No

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Surgery

Locations

Country	Name	City	State
China	linzhu Zhai	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Linzhu Zhai

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Overall survival was defined as the duration between the surgery and death or the last follow-up	2004.1.1-2013.12.31
Secondary	Cancer-specific survival	Cancer-specific survival was defined as the period between the surgery and death due to cancer to reduce the impact of life-threatening comorbidities.	2004.1.1-2013.12.31